Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: Expert Opinions on HIV Cure Research
The Body Covers:
The 7th Conference on Retroviruses and Opportunistic Infections
San Francisco Marriott, San Francisco, California

January 30 - February 2, 2000



The 7th Conference on Retroviruses and Opportunistic Infections draws 3,200 clinicians and basic scientists from around the world to present the latest research on HIV, AIDS, and opportunistic infections. The meeting is sponsored by the Foundation for Retrovirology and Human Health and is in scientific collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) and the Centers for Disease Control and Prevention (CDC).

The Retrovirus Conference, regarded as one of the most important scientific gatherings of the year, was created to provide a forum for scientists and clinicians to present, discuss, and critique developments in the field of human retrovirology and related opportunistic complications. The subjects that will be highlighted are: virology, pathogenesis, host-virus interactions, pathology, immunology, epidemiology, diagnostics, prevention, therapy, pharmacology, and vaccines. In addition, new scientific studies concerning the diagnosis, treatment, and prevention of associated opportunistic infections will be included.

Reporting exclusively for The Body are Alvan Fisher, M.D., Rhode Island Hospital and Associate Professor, Brown University School of Medicine; Ian Frank, M.D., Hospital of the University of Pennsylvania and Associate Professor, University of Pennsylvania; Mark Holodniy, M.D., Veterans Affairs Medical Center and Associate Professor, Stanford University; Paul E. Sax, M.D., Brigham and Women's Hospital (BWH) in Boston and Associate Professor, Harvard Medical School; and Rick Stryker, M.D., Pacific Oaks Medical Group, Los Angeles, CA; Melanie A. Thompson, M.D., AIDS Research Consortium of Atlanta; Doug Ward, M.D., Dupont Circle Physicians Group, Washington, D.C.

In addition, the Seattle Treatment Education Project (STEP), publisher of the treatment journal, STEP Perspective, will be providing additional conference summaries. STEP reporters include: Dan Dawson, Editor of the STEP Perspective.

Funding for this conference coverage at The Body is provided, in part, by unrestricted educational grants from Agouron Pharmaceuticals, Bristol-Myers Squibb, DuPont Pharmaceuticals Company, Glaxo Wellcome, and Roxane Laboratories.


The Body's Conference Summaries
Day One
Sunday,
January 30
Day Two
Monday,
January 31
Day Three
Tuesday,
February 1
Day Four
Wednesday,
February 2
Opening Session

Metabolic Abnormalities/Fat Redistribution: Prevalence, Incidence, and Risk Factors

Gender Differences in Body Habitus Changes/Fat Redistribution

Cardiovascular Complications of Antiretroviral Therapy

Pathogenesis and Mechanisms of Metabolic Abnormalities

Metabolic Complications: Effects of Switching Antiretroviral Therapy and Other Interventions

Complications of Therapy: Mitochondrial Dysfunction/Lactic Acidosis

Adherence to Chemotherapeutic Regimens

Pharmacology: Drug Interactions

Pharmacology of Antiretroviral Drugs

New Drug Targets: Integrase Inhibitors

Emerging Issues in Hepatitis C Infection

Metabolic Complications of Antiretroviral Therapy

Management of the HIV-Infected Pregnant Woman

HIV Entry and Its Inhibition

Primary Infection

Antiviral Therapy: Resistance and Reservoirs

Primary and Secondary Prevention of Opportunistic Infections in the Era of HAART

Pathogenesis and Treatment of Mycobacterial Infections

Pathogenesis and Treatment of CMV Disease in the Era of HAART

HIV-1 Dementia, PML, and Neurologic Complications of Therapy

Metabolic Complications of Antiviral Therapy

Immune Reconstitution in Pediatric HIV-1 Infection

Immunotherapy and Treatment Interruption

Timing the Origin of the HIV Pandemic

Antiviral Therapy: Clinical Trials

Trends in HIV-Associated Mortality

Novel Antiretroviral Agents: Protease Inhibitors

Antiretroviral Therapy in Treatment-Naïve Patients

Antiretroviral Chemotherapy: Treatment-Experienced Patients

Immune-Based and Genetic Therapies

Treatment of Primary Infection

Critical Issues in Antiretroviral Therapy

Pediatric/Maternal-Fetal Treatment Issues

Antiviral Therapy: New Drugs

Issues in HIV-1 Infection in Women

Maternal/Fetal and Pediatric Pharmacokinetics of Antiretroviral Therapy

Resistance to Antiretroviral Drugs

Genotypic and Phenotypic Characterization of HIV for Therapeutic Decision-Making

Documentation of HIV-1 Superinfection and Acceleration of Disease Progression

It Is Safe to Discontinue Secondary Prophylaxis for PCP in HIV-Infected Patients Treated with HAART

Pharmacokinetic Interactions between Protease Inhibitors and Selected HMG-CoA Reductase Inhibitors

A Randomized, Placebo-Controlled Trial of Saquinavir, Indinavir or Nelfinavir in Combination with Amprenavir, Abacavir, Efavirenz & Adefovir in Patients with PI Failure

Virologic and Immunologic Evaluation of Structured Treatment Interruptions in Patients Experiencing Long-term Virologic Failure

Structured Cyclic Antiretroviral Therapy Interruption in Chronic Infection May Induce Immune Responses Against HIV-1 Antigens Associated with Spontaneous Drop in Viral Load



Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

Advertisement